We may be approaching a paradigm shift where the lines between engineering and medicine become blurred. The cATMP® bionic pancreas represents a significant milestone as the world’s first fully functional organ bioprinted using 3D technology. This pioneering development holds great potential as a viable solution capable of producing insulin, glucagon, and C-peptide in a manner consistent with natural human physiology. The capacity to produce an organ ‘on demand’ and store it safely in a dedicated bioreactor until transplantation raises fundamental questions about the future of metabolic disease treatment and the potential of personalised regenerative medicine.
Polbionica, the company based in Zielona Góra that developed this technology, was awarded the main prize in the ‘Polish Product of the Future’ competition, and rightly so. The award, granted by the Polish Agency for Enterprise Development, serves as a testament to the quality and technological maturity of the project. It also highlights the significant contribution of Polish scientific and business expertise to the global future of medicine.
As we consider the potential of bioprinted organs to become a new standard of therapy, we must also consider whether the innovations presented in the competition will become the basis for the country’s technological advantage. This is certainly a topic that deserves discussion.
The transplant of the future? A bionic pancreas as a response to organ shortage
Despite enormous technological progress, the treatment of diabetes has remained essentially a substitution therapy rather than a corrective one. Insulin therapy and insulin pumps respond to glucose levels, but do not regulate metabolism in a physiological manner.
In the absence of a dynamic, dual-hormonal balance between insulin and glucagon, which is of course vital to a healthy body, patients are at risk of developing secondary complications despite optimal glycaemic control. This suggests that we must consider whether we are treating the disease itself or merely its symptoms.
Read more: 3D printing in medical diagnostics and education
Against this background, the bionic pancreas developed by Polish engineers from Polbionica does not represent another iteration of existing solutions, but rather a paradigm shift. This approach is unique in that it does not imitate the function of the organ with an algorithm, but reproduces it biologically with living cells, an integrated vascular system and the ability to comprehensively regulate blood glucose levels. Therefore, this is not a device that dispenses a hormone, but rather an organ that responds independently to the body’s needs. The difference is fundamental and has direct clinical consequences.
The potential of this solution extends far beyond type 1 diabetes itself. The possibility of treating severe complications and chronic pancreatitis, while at the same time providing a real answer to the chronic shortage of organs for transplantation, places the bionic pancreas at the centre of the debate on the future of transplantology. Furthermore, its use as a research tool represents a significant advancement in testing drugs and therapies on a functioning, living organ rather than on simplified models.
ATMP, EMA and bioprinting: is the bionic pancreas closer to the patient than we think?
Recently completed preclinical studies on large animals are now at the stage of being a real test of the organ’s functionality in conditions similar to those in humans, rather than simply demonstrating proof of concept.
Ensuring consistent blood flow through a bioprinted organ is a key challenge in tissue engineering. Without proper perfusion, even the most meticulously designed structure is at risk of necrosis. The successful resolution of this issue significantly mitigates the probability of failure in subsequent development phases.
In addition, data demonstrating a decrease in insulin requirements is equally significant. This indicates that the bioprinted pancreas not only has anatomical integrity, but also performs a metabolic function, influencing the regulation of blood glucose levels throughout the body. In the context of diabetes, a disease that affects hundreds of millions of people worldwide and generates enormous systemic costs, even a partial restoration of physiological control of carbohydrate metabolism can have groundbreaking clinical and economic significance.
The opinion of the European Medicines Agency is also of great importance. The classification of the bionic pancreas as an advanced therapy medicinal product (ATMP) signifies that the project has been evaluated under one of the world’s most rigorous regulatory regimes.
This is not merely an ‘innovation on the margins of the system’; it is a solution that has been moving towards real clinical application from the outset. For investors, clinicians and regulators, this signals the technology’s maturity. The next step, clinical trials, will be pivotal.
The next stage of the process will determine the translation of results from animal models into safety, efficacy and reproducibility of effects in humans. It should also be noted that preparation for clinical trials in the field of bioprinted organs places the project among the most advanced biotechnology initiatives worldwide.
In a broader perspective, a printed organ is just one example of how bioprinting organs ‘on demand’ can transform the paradigm of transplantology. The chronic shortage of organs for transplantation is not a logistical issue, but a structural one. Demand far exceeds supply. Technological advancements in the field of regenerative medicine offer a promising solution to the challenges faced in organ transplantation. By enabling the generation of functional organs, this technology holds the potential to significantly impact healthcare systems. Specifically, it can be used to reduce the waiting times for organ transplants, minimise immune-related complications, and lower the costs associated with long-term care.
At the same time, a pertinent question arises: will bioprinted organs become the standard in personalised medicine, or will they remain a niche solution for the most severe cases? Where is the line between cost-effectiveness, accessibility and ethics? As we consider the implications of this emerging technology, it is vital to assess whether our healthcare systems are prepared for a paradigm shift in the field of transplantation.
The intersection of science and strategic decision-making marks the onset of this crucial discussion.
